Cowen analyst Phil Nadeau noted that Dynavax has restructured to focus on the commercialization of Heplisav and will seek strategic alternatives for the future development of its immunooncology programs, including SD-101. The analyst, whose model had no assumptions for SD-101 product revenue, said he continues to think Dynavax shares are “dramatically undervalued” given the potential of Heplisav in HBV and he also believes the company has sufficient cash to make it a success. He keeps an Outperform rating and $30 price target on Dynavax.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.